## (19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 10 September 2004 (10.09.2004)

PCT

(10) International Publication Number WO 2004/075842 A3

(51) International Patent Classification7: C0711 21/04

C07K 13/00,

(21) International Application Number:

PCT/US2004/005335

(22) International Filing Date: 24 February 2004 (24.02.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/450,071

25 February 2003 (25.02.2003)

(71) Applicant (for all designated States except US): DANA-FARBER CANCER INSTITUTE, INC. [US/US]: 44 Binney Street, Boston, MA 02115 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHEN, Lan Bo [US/US]; 184 East Emmerson Road, Lexington, MA 02420 (US). AUCLAIR, Daniel [CA/US]; 2 Alonquin Trail, Ashland, MA 01721 (US).

(74) Agent: FRASER, Janis, K.; Fish and Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM. TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:


with international search report

(88) Date of publication of the international search report: 10 November 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MRP3 GENES AND USES THEREOF

(57) Abstract: A nucleic acid capable of driving the expression of a reporter gene in a cancer cell line is disclosed. A polypeptide able to confer multidrug-resistance on a cell is disclosed. Also disclosed are nucleic acids encoding the polypeptide, expression vectors, transformant host cell lines expressing the polypeptide, and antibodies binding to the polypeptide. Screening, diagnostic and treatment methods using the above polypeptide, nucleic acids, antibodies and host cell lines are also within the scope of this



International application No.

PCT/US04/05335

TO THE PROPERTY OF STREET MATTER						
A CLASSIFICATION OF SUBJECT MATTER  IPC(7) : C07K 13/00; C07H 21/04						
PC(7) : C07K 13/00; C07H 21/04 US CL : 530/350; 536/22.1; 435/252.3, 325						
According to International Patent Classification (IPC) or to both national classification and IPC						
B. FELDS SEARCHED						
	cumentation searched (classification system followed by	classificat	ion symbols)			
118 - 53	0/350; 536/22.1; 435/252.3, 325			<b>,</b>		
0.3 33	(/JJ0, J3(/ZZ,1, /JZ/ZZZ,0, CZ)					
	included in the Golde coarched					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
NONE						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)						
Please See Continuation Sheet						
Flease See Community Sheet						
C. DOCT	UMENTS CONSIDERED TO BE RELEVANT		Salar and assert managers	Relevant to claim No.		
Category *	Citation of document, with indication, where ap	propriate, c	of the relevant passages	1-12 and 24		
A	DUSSAULT et al. Peptide Mimetic HIV Protease In	hibitors Ar	e ligands for the Orphan	1-12 and 24		
	Receptor SXR. The Journal of Biological Chemisry.	2001, VOI.	276, 146. 36, pages 333074			
	33312.			\		
	Dayamhiain Effice	ov in Patien	uts with Recurrent High-	1-12 and 24		
A	HAU et al. Pegylated Liposomal Doxorubicin-Efficacy in Patients with Recurrent High- Grade Glioma. Cancer. 2004, Vol. 100, No. 6, pages 1199-1207.		,	ì		
	Grade Glioma, Cancer. 2004, Vol. 100, 140. 0, pages		•			
ļ				Ĭ		
				1		
				į		
1			_			
				_		
·				·		
				ļ l		
				]		
1						
				L		
	The state of the s		See patent family annex.			
. —	er documents are listed in the continuation of Box C.		later document published after the inter	national filing date or priority date		
•	Special categories of cited documents:	"T"	and not in conflict with the application	but cited to understand the		
"A" documen	nt defining the general state of the art which is not considered to be of		principle or theory underlying the inver	ition		
particula	ur relevance	"X"	document of particular relevance; the c	laimed invention cannot be		
"E" earlier a	pplication or patent published on or after the international filing date		considered novel or cannot be consider when the document is taken alone	ed to involve an inventive step		
1	at which may throw doubts on priority claim(s) or which is cited to					
"L" docume: establish	n the publication date of another citation or other special reason (as	"Y"	document of particular relevance; the e considered to involve an inventive step	laimed invention cannot be		
specifie			with one or more other such documents	s, such combination being obvious		
"O" docume	nt referring to an oral disclosure, use, exhibition or other means		to a person skilled in the art			
''D" desume	nt published prior to the international filing date but later than the	"&"	document member of the same patent	family		
priority	"P" document published prior to the international filing date but later than the priority date claimed					
Data of the	Date of the actual completion of the international search  Date of the international search report					
Date of the actual completion of the international scatch			-a AUG ZUUS			
11 April 2005 (11.04.2005)						
Name and r	nailing address of the ISA/US	Authoriz	Witten Soul	TINAS (. 1		
Mail Stop PCT, Attn: ISA/US		Gary Benzion Thursexce for				
Commissioner for Patents P.O. Box 1450		T. 1. 1.	Telephone No. (571) 272.1600			
Alexandra, vingata 22515-1450			ne 140. (3/1) 2/2.1000			
Facsimile N	No. (703) 305-3230	<u></u>				

Form PCT/ISA/210 (second sheet) (January 2004)



# INTERNATIONAL SEARCH REPORT


International application No.

PCT/US04/05335

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)			
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:			
1.	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:		
2.	Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:		
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).		
Box No. III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)		
	ional Searching Authority found multiple inventions in this international application, as follows: Continuation Sheet		
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:		
4. Remark on	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.		

Form PCT/ISA/210 (continuation of first sheet(2)) (January 2004)





#### INTERNATIONAL SEARCH REPORT

BOX III. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-12 and 24, drawn to an isolated nucleic acid comprising a nucleotide sequence which is at least 70% identical to the sequence of SEQ ID NO: 3 encoding with the amino acid sequence of SEQ ID NO: 2 and method of producing a polypeptide by using the sequence.

Group II, claim(s) 13-16, drawn to a nucleic acid sequence further comprising SEQ ID NO: 1.

Group III, claim(s) 17-18, drawn to an isolated polypeptide comprising an amino acid sequence which is at least 70% identical to the amino acid sequence of SEQ ID NO: 2.

Group IV, claim(s) 19-22, drawn to an expression vector comprising a first nucleic acid sequence comprising SEQ ID NO: 3 and a second nucleic acid sequence encoding a gene.

Group V, claim(s) 23, drawn to a purified antibody.

Group VI, claim(s) 25-30, drawn to a method for detecting a cellular proliferative disorder in a subject via measuring the level of a gene encoding a polypeptide with sequence of SEQ ID NO 2.

Group VII, claim(s) 31-33, drawn to a method for monitoring a subject undergoing a therapeutic treatment.

Group VIII, claim(s) 34, drawn to a method for targeting a cellular proliferative disorder in a subject.

Group IX, claim(s) 35, drawn to a method for expression a foreign polypeptide in a cell in vivo.

Group X, claim(s) 36, drawn to a method for introducing a foreign nucleic acid into a cell in vivo.

Form PCT/ISA/210 (extra sheet) (January 2004)





### INTERNATIONAL SEARCH REPORT

International application No. PCT/US04/05335

Group XI, claim(s) 37 drawn to a method for targeting a cellular proliferative disorder in a subject via administering to the subject an agent that can bind to a nucleic acid comprising the nucleotide of SEQ ID NO: 3,

Group XII, claim(s) 38, drawn to a method for targeting a cellular proliferative disorder in a subject via administering to the subject an agent that can modulate the expression level of a gene encoding to a polypeptide comprising the amino acid sequence of SEQ ID NO: 2.

Group XIII, claim(s) 39, drawn to a method for modulating the cellular pump mechanism of a resistant tumor cell.

Group XIV, claim(s) 40, drawn to a method for modulating the cellular pump mechanism of a resistant tumor cell via administering to a subject having a resistant tumor cell an agent that binds to a polypeptide comprising the amino acid sequence of SEQ ID NO: 2.

Group XV, claim(s) 41-43, drawn to a method for screening for a therapeutic agent for treating a drug-resistant tumor cell.

Group XVI, claim(s) 44-46, drawn to a cell for screening for a therapeutic agent for treating a drug-resistant tumor cell.

Group XVII, claim(s) 47, drawn to a method for making an antibody by immunizing a non-human animal with an immunogenic fragment of a polypeptide with the sequence of SEQ ID NO: 2.

Group XVIII, claim(s) 48, drawn to a method for making an antibody comprising providing a hybridoma cell.


Group XIX, claim(s) 49, drawn to a method for modulating expression of a gene responsible for controlling cellular pump mechanisms in cell.

Group XX, claim(s) 50, drawn to a method for delivering a suicide protein to a tumor cell.

The inventions listed as Groups I-XX do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The Products groups I-V and XVI claim different products, for example, Groups I and II are drawn to nucleic acid, Group III is drawn to polypeptide, Group IV is drawn to an expression vector which comprises different sequences from the nucleic acid sequence claimed in Groups I and II. Group V is drawn to antibody, and Group XIV is drawn to a cell for screening for a therapeutic agent. Because of the different molecular structures of the products, thus, they are different invention.

Among Groups I and II, Group I is drawn to an isolated nucleic acid comprising a nucleotide sequence which is at least 70% identical to the sequence of SEQ ID NO: 3, while Group II is drawn to a nucleic acid sequence further comprising SEQ ID NO: 1.



International application No. PCT/US04/05335

The method Groups VI-XV and XVII-XX are drawn to different methods as set forth in their preambles and the different method steps. Thus they lack the same or corresponding special technical features.			
Continuation of B. FIELDS SEARCHED Item 3: WEST AND STN SEARCHED; MEDLINE, CAPLUS, BIOSIS, EMBASE. search terms: SEQ ID NO: 3 and 2, producing polypeptide, expression vector			